Apoptosis, cellular proliferation and expression of p53 in human uterine leiomyomas and myometrium during the menstrual cycle and after menopause

Acta Obstetricia et Gynecologica Scandinavica

Volumn 79, Issue 5, 2000, Pages 397-404

  Wu, Xuxia ^a   Blanck, Agneta ^b   Olovsson, Matts ^a   Möller, Björn ^a   Favini, Roberta ^a   Lindblom, Bo ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Apoptosis; Cellular proliferation; Leiomyomas; Myometrium; p53

Indexed keywords

DNA; KI 67 ANTIGEN; PROTEIN P53;

APOPTOSIS; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DEGRADATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MENOPAUSE; MENSTRUAL CYCLE; MYOMETRIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; UTERUS MYOMA;

ADULT; APOPTOSIS; BLOTTING, WESTERN; CELL DIVISION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU NICK-END LABELING; KI-67 ANTIGEN; LEIOMYOMA; MENOPAUSE; MENSTRUAL CYCLE; MIDDLE AGED; MYOMETRIUM; TUMOR SUPPRESSOR PROTEIN P53; UTERINE NEOPLASMS;

EID: 0034018921     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0412.2000.079005397.x     Document Type: Article

References (25)

1. 1. Kawaguchi K, Fujii S, Konishi I et al. Ultrastructural study of cultured smooth muscle cells from uterine leiomyomas and myometrium under the influence of sex steroids. Gynecol Oncol 1985; 21: 34-41.
2. 2. Kanetoshi K, Shingo F, Ikuo K et al. Immunohistochemical analysis of estrogen receptors, progesterone receptors and ki-67 in leiomyoma and myometrium during the menstrual cycle and pregnancy. Virchows Archiv A Pathol Anat 1991; 419: 309-15.
3. 3. Gerdes J, Lelle RJ, Pickartz H. Growth fraction in breast cancer determined in situ with the monoclonal antibody ki-67. J Clin Pathol 1986; 39: 977-80.
4. 4. Kubota Y, Petras RE, Easley KA et al. Ki-67-determined growth fraction versus standard staging and grading parameters in colorectal carcinoma. A multivariate analysis. Cancer 1992; 70: 2602.
5. 6. Bosman FT, Visser BC, Oeveren JV. Apoptosis: Pathophysiology of programmed cell death. Pathol Res Pract 1996; 192: 676-83.
6. 7. Lowe SW, Schmitt EM, Smith SW et al. P53 is required for radiation induced apoptosis in mouse thymocytes. Nature 1993; 362: 847-9.
7. 8. Zhai YL, Kobayashi Y, Mori A et al. Expression of steroid receptors, ki-67 and p53 in uterine leiomyosarcomas. Int J Gynecol Pathol 1999 Jan; 18(1): 20-8.
8. 8. Gavrieli Y, Sherman Y, Ben-Sasson SA. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 1992; 119: 493-501.
9. 9. Gerdes J, Lemke H, Baisch H et al. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody ki-67. J Immunol 1984; 133: 1710-15.
10. 10. Hall PA, Levison DA. Assessment of cellular proliferation in histological material. J Clin Pathol 1992; 43: 184-92.
11. 11. Kanetoshi K, Shingo F, Ikuo K et al. Mitotic activity in uterine leiomyomas during the menstrual cycle. Am J Obstet Gynecol 1989; 160: 637-41.
12. 12. Takahiro M, Ayako S, Karo N, Nobuyuki T. Suppression of cell proliferation and induction of apoptosis in uterine leiomyoma by gonadotropin-releasing hormone agonist (Leuprolide acetate). J Clin Endocrinol Metab 1998; 83: 1253-5.
13. 13. Brandon DD, Bethea CL, Strawn EY et al. Progesterone receptor messenger ribonucleic acid and protein are overexpressed in human uterine leiomyomas. Am J Obstet Gynecol 1993; 69: 78-85.
14. 14. Brandon DD, Erickson TE, Keenan EJ et al. Estrogen receptor gene expression in human uterine leiomyoma. J Clin Endocrinol Metab 1995; 80: 1876-81.
15. 15. Englund K, Blanck A, Gustavsson I et al. Sex steroid receptors in human myometrium and fibroids: changes during the menstrual cycle and treatment with gonadotropin-releasing hormone analogue. J Clin Endocrinol Metab 1998; 83(11): 4092-6.
16. 16. Sadan O, van Iddekinge B, Savage N et al. Endocrine profile associated with estrogen and progesterone receptors in leiomyoma and myometrium. Gynecol Endocrinol 1991; 4: 33-42.
17. 17. Murphy AA, Kettle M, Morales AJ et al. Regression of uterine leiomyomata in response to the antiprogesterone RU486. J Clin Endocrinol Metab 1993; 76: 513-17.
18. 18. Tiltman AJ. The effect of progestins on the mitotic activity of uterine fibromyomas. Int J Gynecol Pathol 1985; 4: 89-96.
19. 19. Boehm KD, Daimon M, Gorodeski IG. Expression of the insulin-like and platelet-derived growth factor genes in human uterine tissues. Mol Reprod Dev 1990; 27: 93-101.
20. 20. Ghahary A, Chakrabarti S, Murphy LH. Localization of the sites of synthesis and action of insulin-like growth factor-1 in the rat uterus. Mol Endocrinol 1990; 4: 191-5.
21. 21. Wang XN, Sanjoy KD, Deborah D et al. Differential regulation of heparin-binding epidermal growth factor-like growth factor in the adult ovariectomized mouse uterus by progesterone and estrogen. Endocrinology 1994; 135: 1264-71.
22. 22. Rotello RJ, Hocker MB, Gerschenson LE. Biochemical evidence of programmed cell death in rabbit uterine epithelium. Am J Pathol 1989; 134: 491-5.
23. 23. Anderson TJ, Ferguson DJP, Raab GM. Cell turnover in the 'resting' human breast: influence of parity, contraceptive pill, age and laterality. Br J Cancer 1982; 46: 376-82.
24. 24. Soini Y, Pääkkö P. Bcl-2 is preferentially expressed in tumors of muscle origin but is not related to p53 expression. Histopathology 1996; 28: 141-5.
25. 25. Patterson H, Gil S, Fisher C et al. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas. Br J Cancer 1994; 69: 1052-8.